IRSF announces the availability of Regular Research grants for international biomedical research to promote the understanding of MeCP2 in the pathogenesis of the neurobehavioral phenotype of Rett syndrome (RTT). We seek to gain a better understanding of the underlying pathology of the disorder leading to an amelioration of the symptoms and a cure for RTT. IRSF seeks to encourage research that encompasses innovative therapeutic approaches and state of the art diagnostic techniques.
IRSF encourages applications within the following emphasis areas:
- Understanding the role of MeCP2 during normal brain development
- Characterizing the role of MeCP2, including MeCP2 target genes, in normal structure and function of the developing and adult nervous system
- Determination of the relationship between patterns of expression of MeCP2, FoxG1, CDKL5, and related proteins in the nervous system and the neurologic and behavioral phenotypes of patients with RTT and/or related animal models
- The investigation of neuronal abnormalities that result from MeCP2 dysfunction
- The role of microglial and macroglial cells in development as it relates to RTT
- Understanding mechanisms and systems leading to aberrant behavior in RTT
- The development of assistive technologies to improve the quality of life of individuals affected by RTT
- Support for other advances in therapy such as physical therapy, communication and education
The two year Regular Research Grants are designed to assist investigators establish hypotheses relevant to Rett syndrome research and obtain future funding from other agencies. The maximum funding level for research grants is $100,000 over two years.
||Awards will be made in one cycle in 2013
||Letters of Intent due: July 1, 2013
|Invitation of full applications by: July 19, 2013
|Applications due: August 19, 2013